NovoCure (NASDAQ:NVCR) Releases Quarterly Earnings Results, Beats Estimates By $0.14 EPS

NovoCure (NASDAQ:NVCR) announced its quarterly earnings results on Thursday. The medical equipment provider reported ($0.09) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.23) by $0.14, FiscalAI reports. NovoCure had a negative net margin of 21.25% and a negative return on equity of 44.00%. The company had revenue of $193.40 million during the quarter, compared to the consensus estimate of $182.28 million. During the same period in the prior year, the business earned ($0.33) earnings per share. The company’s revenue for the quarter was up 15.7% compared to the same quarter last year.

Here are the key takeaways from NovoCure’s conference call:

• Q3 net revenue rose 16% year over year to $193 million, driven by 19% growth in active patients, stronger Optune Gio performance, and contributions from Optune Lua and Optune Pax. The company raised its 2026 revenue guidance to $736 million–$743 million.
• Optune Gio active patients reached a record 4,729, up 11% year over year, while Optune Lua’s Japan launch gained momentum with 110 Japanese patients and $4 million in quarterly revenue. Management expects Japan to become NovoCure’s second-largest market behind the U.S.
• The Optune Pax launch faced significant U.S. headwinds after the introduction of daraxonrasib, with practices reportedly overwhelmed by reimbursement appeals and treatment-related skin irritation; Pax ended the quarter with 276 active patients and $3.7 million in revenue. NovoCure expects to rebuild momentum through improved commercial execution, NCCN guideline inclusion, and planned combination studies with KRAS inhibitors.
• Profitability metrics improved substantially, with adjusted EBITDA of $16 million versus negative $3 million a year earlier and updated full-year adjusted EBITDA guidance of $24 million–$34 million. Management cautioned that quarterly results may fluctuate, but said its next objective is cash-flow breakeven.
• The FDA is reviewing the Optune Mya application for brain metastases from non-small cell lung cancer, with a decision expected by year-end and a potential early-2027 launch. KEYNOTE-D58 enrollment remains on track for completion by year-end, supporting potential future GBM growth.

NovoCure Trading Down 6.9%

Shares of NVCR traded down $0.97 during mid-day trading on Thursday, reaching $13.20. 3,645,647 shares of the company were exchanged, compared to its average volume of 1,671,390. The business has a 50 day simple moving average of $15.98 and a two-hundred day simple moving average of $14.80. The company has a debt-to-equity ratio of 0.58, a quick ratio of 2.70 and a current ratio of 2.89. The stock has a market capitalization of $1.54 billion, a PE ratio of -10.09 and a beta of 0.99. NovoCure has a 52 week low of $9.82 and a 52 week high of $21.45.

Analyst Ratings Changes

NVCR has been the subject of a number of recent research reports. JPMorgan Chase & Co. initiated coverage on NovoCure in a report on Monday, July 13th. They issued a “neutral” rating and a $17.00 target price for the company. Weiss Ratings reissued a “sell (d-)” rating on shares of NovoCure in a research note on Thursday, August 27th. Zacks Research upgraded NovoCure from a “strong sell” rating to a “hold” rating in a report on Friday, July 24th. Wall Street Zen downgraded NovoCure from a “buy” rating to a “hold” rating in a research note on Saturday, October 10th. Finally, Wedbush raised their price objective on shares of NovoCure from $18.00 to $20.00 and gave the company a “neutral” rating in a report on Friday, July 24th. Two research analysts have rated the stock with a Buy rating, four have assigned a Hold rating and one has given a Sell rating to the company. According to MarketBeat, the company presently has an average rating of “Hold” and a consensus price target of $21.20.

NovoCure Company Profile

NovoCure Ltd. (NASDAQ: NVCR) is an oncology company that develops and commercializes therapies based on Tumor Treating Fields (TTFields), low-intensity electric fields designed to disrupt the division of cancer cells. Its treatments are delivered through portable, wearable devices used alongside other cancer therapies.

The company’s principal products include Optune Gio for certain adults with glioblastoma and Optune Lua for adults with unresectable, locally advanced or metastatic pleural mesothelioma and certain forms of metastatic non-small cell lung cancer.